These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 23989987

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 5. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
    Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.
    Ann Rheum Dis; 2014 Apr; 73(4):710-5. PubMed ID: 23505240
    [Abstract] [Full Text] [Related]

  • 6. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
    Henderson C, Davis JC.
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
    Song IH, Maksymowych WP.
    Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
    de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.
    Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E.
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E, Karkucak M, Yayli S, Aydin Çapkin A, Tosun M.
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R.
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract] [Full Text] [Related]

  • 19. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J, Rudwaleit M.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [Abstract] [Full Text] [Related]

  • 20. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
    Sieper J, Appel H, Braun J, Rudwaleit M.
    Arthritis Rheum; 2008 Mar; 58(3):649-56. PubMed ID: 18311819
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.